KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Payables (2016 - 2025)

Historic Payables for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $152.2 million.

  • Jazz Pharmaceuticals' Payables rose 7819.96% to $152.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.2 million, marking a year-over-year increase of 7819.96%. This contributed to the annual value of $77.9 million for FY2024, which is 2421.51% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Payables stood at $152.2 million for Q3 2025, which was up 7819.96% from $89.4 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Payables peaked at $152.2 million during Q3 2025, and registered a low of $63.8 million during Q3 2021.
  • Its 5-year average for Payables is $92.8 million, with a median of $90.8 million in 2022.
  • In the last 5 years, Jazz Pharmaceuticals' Payables surged by 27223.23% in 2021 and then crashed by 3545.36% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Payables (Quarter) stood at $100.3 million in 2021, then decreased by 9.51% to $90.8 million in 2022, then rose by 13.21% to $102.8 million in 2023, then fell by 24.22% to $77.9 million in 2024, then surged by 95.49% to $152.2 million in 2025.
  • Its last three reported values are $152.2 million in Q3 2025, $89.4 million for Q2 2025, and $95.9 million during Q1 2025.